goralatide has been researched along with Diabetic Nephropathies in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Goodwin, JE; Kanasaki, K; Koya, D; Srivastava, SP | 2 |
| Bernstein, EA; Bernstein, KE; Cao, D; Giani, JF; Gonzalez-Villalobos, RA; Khan, Z; Okwan-Duodu, D; Shen, JZY; Veiras, LC | 1 |
| Bernstein, EA; Bernstein, KE; Cao, DY; Eriguchi, M; Fuchs, S; Giani, JF; Gonzalez-Villalobos, RA; Khan, Z; McDonough, AA; Toblli, JE; Veiras, LC | 1 |
| Ishigaki, Y; Kanasaki, K; Kanasaki, M; Kitada, M; Koya, D; Nagai, T; Nakamura, Y; Shi, S; Srivastava, SP | 1 |
| Haneda, M; Kanasaki, K; Kanasaki, M; Kitada, M; Koya, D; Nagai, T; Nitta, K; Shi, S; Srivastava, SP | 1 |
| Bombardi, C; Castoldi, G; Corradi, B; di Gioia, CR; Leopizzi, M; Maestroni, S; Preziuso, C; Stella, A; Zerbini, G | 1 |
| Araki, S; Haneda, M; Isono, M; Isshiki, K; Kanasaki, K; Kashiwagi, A; Koya, D; Omata, M; Sato, H; Shibuya, K; Sugimoto, T | 1 |
| Haneda, M; Isono, M | 1 |
2 review(s) available for goralatide and Diabetic Nephropathies
| Article | Year |
|---|---|
Novel roles of the renal angiotensin-converting enzyme.
Topics: Acute Kidney Injury; Angiotensin I; Angiotensin II; Animals; Blood Pressure; Bradykinin; Diabetic Nephropathies; Gene Expression Regulation; Humans; Hypertension; Kidney; Mice; Oligopeptides; Peptide Fragments; Peptidyl-Dipeptidase A; Renin-Angiotensin System; Signal Transduction; Water-Electrolyte Balance | 2021 |
[Novel therapeutic strategy for diabetic nephropathy].
Topics: Animals; Depression, Chemical; Diabetic Nephropathies; DNA-Binding Proteins; Extracellular Matrix; Humans; Oligopeptides; Phosphorylation; Signal Transduction; Smad Proteins; Trans-Activators; Transforming Growth Factor beta | 2005 |
7 other study(ies) available for goralatide and Diabetic Nephropathies
| Article | Year |
|---|---|
Inhibition of Angiotensin-Converting Enzyme Ameliorates Renal Fibrosis by Mitigating DPP-4 Level and Restoring Antifibrotic MicroRNAs.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Cell Line; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dipeptidyl Peptidase 4; Disease Models, Animal; Drug Synergism; Gene Expression Regulation; Humans; Mice; MicroRNAs; Oligopeptides; Signal Transduction; Transforming Growth Factor beta | 2020 |
Metabolic reprogramming by N-acetyl-seryl-aspartyl-lysyl-proline protects against diabetic kidney disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellitus; Diabetic Nephropathies; Humans; Kidney; Male; Mice; Mice, Inbred C57BL; Oligopeptides | 2020 |
The Absence of the ACE N-Domain Decreases Renal Inflammation and Facilitates Sodium Excretion during Diabetic Kidney Disease.
Topics: Amino Acid Substitution; Angiotensin II; Animals; Catalytic Domain; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Epithelial Sodium Channels; Inflammation; Interleukin-1beta; Kidney; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mutagenesis, Site-Directed; Natriuresis; Oligopeptides; Peptidyl-Dipeptidase A; Protein Domains; Renin-Angiotensin System | 2018 |
N-acetyl-seryl-aspartyl-lysyl-proline inhibits diabetes-associated kidney fibrosis and endothelial-mesenchymal transition.
Topics: Animals; Cytokines; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Epithelial-Mesenchymal Transition; Fibrosis; Growth Inhibitors; Male; Mice; MicroRNAs; Oligopeptides; Receptors, Fibroblast Growth Factor | 2014 |
Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen.
Topics: Administration, Oral; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Imidazolidines; Mice; Mice, Inbred NOD; Oligopeptides; Peptidyl-Dipeptidase A | 2016 |
Renal antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetic Nephropathies; Drug Evaluation, Preclinical; Glomerular Filtration Rate; Growth Inhibitors; Kidney Glomerulus; Male; Membrane Proteins; Nephrosclerosis; Oligopeptides; Ramipril; Rats; Rats, Sprague-Dawley | 2013 |
N-acetyl-seryl-aspartyl-lysyl-proline prevents renal insufficiency and mesangial matrix expansion in diabetic db/db mice.
Topics: Animals; Collagen Type IV; Diabetic Nephropathies; DNA-Binding Proteins; Extracellular Matrix Proteins; Fibronectins; Gene Expression; Glomerular Mesangium; Male; Mice; Mice, Knockout; Oligopeptides; Renal Insufficiency; Smad3 Protein; Trans-Activators; Transforming Growth Factor beta | 2005 |